Compare Mesoblast Limited (MESO) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $117.5. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | QQQE | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $20.96 | $122.72 |
52-Week Low | $12.88 | $96.06 |
Enterprise Value | $2.17B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
